TMCnet News

Mountain Valley MD Announces Appointment of Advisors, Stock Option Grant and Provides Uplisting Update
[July 15, 2021]

Mountain Valley MD Announces Appointment of Advisors, Stock Option Grant and Provides Uplisting Update


TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (FRA:20MP) (OTCQB: MVMDF) is pleased to announce the appointment of Gokul Kannan and Mark Gelnaw as advisors to the Company as well as the grant of stock options. The Company also wishes to provide an update on its TSX-V listing application.

APPOINTMENT OF ADVISORS

The new advisory appointments come at a pivotal time for Mountain Valley MD, as the company actively advances its oncology work and broadens its commercial applications of its desiccated liposome and solubilization technology.

Gokul Kannan

Mr. Kannan is a partner at Zephyr Venture Partners and a rising star in bioengineering & chemical engineering research. He earned a Bachelor of Science from the University of California, Berkeley in Chemical Engineering with a minor in Bioengineering. He has had 7 years of research experience at UC Berkeley, Johns Hopkins, and Gilead, working with doctors Sanjay Kumar, Richard Saykally, Takanori Takebe, and Sapna Kudchadkar, among others.

Mr. Kannan’s research thus far has focused on drug delivery, biomaterials, tissue engineering & regenerative medicine, and physical & medicinal chemistry/chemical engineering. Recently, his work has focused on studying using biomaterials and computational biology to study microglia, glioblastoma & cancer biology, and tissue engineering, with 8 publications in press or under review and multiple cover articles in prominent journals.

Mr. Kannan is an inventor on four pending patents including both therapeutic and device patents. His work has been featured in the New York Times, Science Magazine, The Economist, and more than 15 other major science news outlets. Mr. Kannan, at the young age of 21, has already received a number of major research awards from prominent societies including the American Academy of Neurology, and the Society for Biomaterials.

Mark Gelnaw

Mr. Gelnaw is an esteemed financial executive whose career spans more than 35 years in financial management, business leadership, and corporate strategy, including acting as CEO and CFO for Cynvec LLC, a research-based cancer entity that partnered with NYU in the development of a Sindbis virus for the treatment of ovarian and colon cancer.

Mr. Gelnaw’s past executive roles include Chief Operating Officer of Deutsche Bank, Chief Operating and Financial Officer at Lehman Brothers, senior roles at Salomon Brothers and Arthur Andersen, and founder of Breakwater Ventures which manages a diverse array of investments and strategies across many industry platforms, including Medical Devices, FinTech, Cancer Research and Development, Health and Wellness, Covid 19 Testing and Collection, Real Estate, and financial enterprises.

“I am extremely proud to welcome Gokul and Mark to our Advisory Board at Mountain Valley MD and look forward to their immediate contributions at this critical growth phase of our company,” commented Dennis Hancock, President and CEO of Mountain Valley MD. “he collective knowledge and deep experience brought to our team from our new advisors will be invaluable as we advance our key oncology and technology projects, as well as contributing to our overall business maturation in the biotech space.”



Stock Exchange Listing

On April 20, 2021, the Company announced that it was proceeding with the application for the listing of its shares for trading on the TSX Venture Exchange (“TSXV”). While the Company has proceeded with such application, it is also considering the value proposition of listing on the NEO exchange to achieve its objective of enhanced exposure and liquidity. The NEO Exchange is a recognized Canadian exchange for senior public companies and investment products. Operating since mid-2015, NEO was launched with the stated purpose of providing Canadians with a stock exchange that puts the interest of capital-raising companies, investors and their dealers first.


The Company is reviewing options with its Board of Directors and anticipates making a broader uplisting decision by early August, 2021.

Stock Option Grant

The Company also announces that, pursuant to the Company’s Stock Option Plan, an aggregate of 3,725,000 options have been granted to certain directors, officers, employees and consultants and advisors as incentive stock options at an exercise price of $0.27 per share. The options are exercisable for a period of five years, 20% vesting on the date of grant, 30% on the 6-month anniversary following the date of grant and the remaining 50% on the 12-month anniversary following the date of grant.

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC
Mountain Valley MD is building a world-class biotech and life sciences company organization centered around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies and its Quicksol™ solubilization technology for macrocyclic lactones, to innovate industry leading products that are sought out globally.

MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.

The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.

The Company’s patented Quicksol™ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that only uses excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity. 

For more Company information and contact details, visit www.mountainvalleymd.com.

SOURCE: Mountain Valley MD Holdings Inc.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.

The Company is making forward-looking statements, including its application for the listing of its common shares on the TSX Venture Exchange or the NEO Exchange.

The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

For further information:

www.mountainvalleymd.com


Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Telephone: 647-725-9755
Email: dennis@mountainvalleymd.com

Primary Logo


[ Back To TMCnet.com's Homepage ]